A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers

• Drug: Active
  
  Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
• Drug: Placebo
  
  Two subjects will receive the placebo under fasting condition.
• Drug: Active
  
  Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
• Drug: Active
  
  Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.

• Placebo Comparator: Cohort 1
  
  PF-00868554 (filibuvir) 100 mg or placebo
  Interventions:
  

  • Drug: Active
  • Drug: Placebo
• Placebo Comparator: Cohort 2
  
  PF-00868554 (filibuvir) 300 mg or placebo
  Interventions:
  

  • Drug: Active
  • Drug: Placebo
• Placebo Comparator: Cohort 3
  
  PF-00868554 (filibuvir) 500 mg or placebo
  Interventions:
  

  • Drug: Active
  • Drug: Placebo

Inclusion Criteria:

• Healthy male and female subjects between the ages of 20 and 55 years.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg.

Exclusion Criteria:

• A positive result for Hepatitis B surface antigen (HbsAg) or anti-hepatitis C virus serology, and HIV antigen/antibody.
• Male subjects with a history of subfertility/infertility and other conditions that in the opinion of the investigator may affect fertility.
• Pregnant or nursing females; females of childbearing potential.